Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace.
A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com . A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through these acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The Company's fourth product line is focused on the transplantation market. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com .
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
For Media and Investor Inquiries:
Head of Strategy and Investor Relations
Tel: +1 (508) 556-1377
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
AnGes MG, Inc.23.1.2018 04:46 | pressemeddelelse
AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
SEMAFO Inc.23.1.2018 01:01 | pressemeddelelse
SEMAFO Inc. : Q4 and Annual 2017 Production and Costs in Line
Atico Mining Corporation22.1.2018 22:31 | pressemeddelelse
Atico Reports 2017 Fourth Quarter and Full Year Production Results
Banque Fédérative du Credit Mutuel SA22.1.2018 18:56 | pressemeddelelse
Banque Fédérative du Credit Mutuel: Post Stabilisation Notice
Claroty22.1.2018 18:44 | pressemeddelelse
Claroty Wins Inaugural S4 ICS Detection Challenge
PwC22.1.2018 18:32 | pressemeddelelse
CEO optimism booms despite increasing anxiety over threats to growth
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum